Trial Profile
A Single Arm, Phase II Study of the Anti-Blys Monoclonal Antibody, Belimumab in Symptomatic Waldenstroms Macroglobulinaemia.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Belimumab (Primary)
- Indications Waldenstrom's macroglobulinaemia
- Focus Adverse reactions
- 23 Nov 2012 Trial association and lead centre changed from Human Genome Sciences to GlaxoSmithKline as Human Genome Sciences is acquired by GlaxoSmithKline.
- 14 Jun 2010 New trial record